Journal Article
. 2019 Jan;9().
doi: 10.3389/fgene.2018.00638.

The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes

Jun Wang 1 Zhen-Yu He 2 Yong Dong 3 Jia-Yuan Sun 2 Wen-Wen Zhang 2 San-Gang Wu 1 
  • PMID: 30619463
  •     32 References
  •     5 citations


Background: The clinical value of 21-gene recurrence score (RS) in various breast cancer histologic subtypes is not well established. Aims: To assess the distribution and outcomes of the 21-gene RS among various T1-T2N0 estrogen receptor-positive breast cancer histologic subtypes. Methods: Using the Surveillance, Epidemiology and End Results database, we investigated the distribution and outcomes of the 21-gene RS among various breast cancer histologic subtypes between 2004 and 2015. The histologic subtypes with 200 or more cases were further analyzed. Results: We identified 83,665 patients including eight histologic subtypes. The most common subtype was invasive ductal carcinoma not otherwise specified (IDC NOS) (77.9%), followed by lobular carcinoma NOS, mixed infiltrating duct and lobular carcinoma (IDC-L), mucinous adenocarcinoma, tubular adenocarcinoma, micropapillary ductal carcinoma, cribriform carcinoma NOS, and intraductal papillary adenocarcinoma with invasion with 10.8, 7.7, 2.1, 0.6, 0.3, 0.2, and 0.2%, respectively. The 5-years breast cancer specific survival (BCSS) was 98.8, 98.8, 98.9, 99.6, 100, 100, 100, and 100%, respectively (P = 0.011). Patients with IDC NOS (8.9%), micropapillary ductal carcinoma (8.8%), and intraductal papillary adenocarcinoma with invasion (8.2%) had significantly higher percentage of high-risk RS compared to other histologic subtypes (1.0-3.8%) (P < 0.001). The mean RS was higher in IDC NOS, lobular carcinoma NOS, and IDC-L compared to other subtypes. In multivariate analysis, 21-gene RS was the independent prognostic factor in patients with IDC NOS (P < 0.001), lobular carcinoma NOS (P < 0.001), and IDC-L (P < 0.001), patients with a higher RS was associated with poor BCSS. Conclusion: Our results demonstrate that there is a significant difference in distribution of 21-gene RS in T1-T2N0 estrogen receptor-positive breast cancer with different histologic subtypes. Long-term studies with larger series are needed to confirm the role of the 21-gene RS array in prognosis assessment and chemotherapy decision-making in special histologic subtypes with favorable prognosis.

Keywords: Oncotype DX; SEER; breast cancer; histologic subtypes; survival.

Special types of invasive breast cancer, with clinical implications.
David L Page.
Am J Surg Pathol, 2003 May 27; 27(6). PMID: 12766589
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Clinical characteristics of different histologic types of breast cancer.
C I Li, D J Uribe, J R Daling.
Br J Cancer, 2005 Sep 22; 93(9). PMID: 16175185    Free PMC article.
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.
Soonmyung Paik.
Oncologist, 2007 Jul 03; 12(6). PMID: 17602054
Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast.
Emad A Rakha, Maysa E El-Sayed, +3 authors, Ian O Ellis.
Breast Cancer Res Treat, 2007 Oct 12; 111(1). PMID: 17929165
Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
Emad A Rakha, Maysa E El-Sayed, +9 authors, Ian O Ellis.
Eur J Cancer, 2007 Nov 24; 44(1). PMID: 18035533
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.
Bernhard C Pestalozzi, David Zahrieh, +13 authors, International Breast Cancer Study Group.
J Clin Oncol, 2008 May 07; 26(18). PMID: 18458044
Breast carcinoma--rare types: review of the literature.
R Yerushalmi, M M Hayes, K A Gelmon.
Ann Oncol, 2009 Jul 16; 20(11). PMID: 19602565
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Lobular breast carcinoma and its variants.
Emad A Rakha, Ian O Ellis.
Semin Diagn Pathol, 2010 Mar 24; 27(1). PMID: 20306830
Histological types of breast cancer: how special are they?
Britta Weigelt, Felipe C Geyer, Jorge S Reis-Filho.
Mol Oncol, 2010 May 11; 4(3). PMID: 20452298    Free PMC article.
Highly Cited. Review.
Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Jessica F Partin, Eleftherios P Mamounas.
Ann Surg Oncol, 2011 May 04; 18(12). PMID: 21537874
The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.
Tomoya Nagao, Takayuki Kinoshita, +3 authors, Yasuhiro Fujiwara.
Breast, 2012 Jan 27; 21(3). PMID: 22277312
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007).
William B Wong, Scott D Ramsey, +2 authors, David L Veenstra.
Contemp Clin Trials, 2012 Sep 18; 33(6). PMID: 22981891    Free PMC article.
Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance.
Patricia A Ganz, Lorna Kwan, +7 authors, Thomas R Belin.
J Natl Cancer Inst, 2013 Apr 23; 105(11). PMID: 23606729    Free PMC article.
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma.
Sibylle Loibl, Cristina Volz, +19 authors, Michael Untch.
Breast Cancer Res Treat, 2014 Feb 08; 144(1). PMID: 24504379
Comparison of SEER Treatment Data With Medicare Claims.
Anne-Michelle Noone, Jennifer L Lund, +4 authors, Joan L Warren.
Med Care, 2014 Mar 19; 54(9). PMID: 24638121    Free PMC article.
Highly Cited.
Cardiovascular toxicities from systemic breast cancer therapy.
Shuang Guo, Serena Wong.
Front Oncol, 2014 Dec 30; 4. PMID: 25538891    Free PMC article.
Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?
Niamh Conlon, Dara S Ross, +3 authors, Lee K Tan.
Breast J, 2015 Aug 15; 21(5). PMID: 26271749    Free PMC article.
Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
Joan Albanell, Christer Svedman, +6 authors, Wolfgang Eiermann.
Eur J Cancer, 2016 Aug 22; 66. PMID: 27544930
Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Carlos H Barcenas, Akshara Raghavendra, +10 authors, Debu Tripathy.
Cancer, 2017 Feb 16; 123(13). PMID: 28199747    Free PMC article.
Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
Yanjun Hou, Gary Tozbikian, Debra L Zynger, Zaibo Li.
Am J Clin Pathol, 2017 Apr 28; 147(6). PMID: 28449064
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Gulisa Turashvili, Edi Brogi, +4 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jun 04; 165(1). PMID: 28577081    Free PMC article.
Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
Scott Kizy, Jing Li Huang, +2 authors, Jane Yuet Ching Hui.
Breast Cancer Res Treat, 2017 Jun 26; 165(3). PMID: 28647915
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
Ian Krop, Nofisat Ismaila, +10 authors, Vered Stearns.
J Clin Oncol, 2017 Jul 12; 35(24). PMID: 28692382    Free PMC article.
Highly Cited.
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
Gulisa Turashvili, Joanne F Chou, +5 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jul 14; 166(1). PMID: 28702894    Free PMC article.
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379    Free PMC article.
Highly Cited.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +21 authors, Nicky Liebermann.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900633    Free PMC article.
Distribution of 21-Gene Recurrence Scores Among Breast Cancer Histologic Subtypes.
Scott Kizy, Jing Li Huang, +5 authors, Jane Yuet Ching Hui.
Arch Pathol Lab Med, 2018 Mar 13; 142(6). PMID: 29528718
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.
Audree B Tadros, Hannah Y Wen, Monica Morrow.
Ann Surg Oncol, 2018 Aug 11; 25(11). PMID: 30094484    Free PMC article.
Impact of the 21-gene recurrence score assay on chemotherapy decision making and outcomes for breast cancer patients with four or more positive lymph nodes.
Qing-Hong Zhang, Wen-Wen Zhang, +4 authors, San-Gang Wu.
Ann Transl Med, 2019 Nov 09; 7(18). PMID: 31700882    Free PMC article.
A Risk Stratification Model for Predicting Overall Survival and Surgical Benefit in Triple-Negative Breast Cancer Patients With de novo Distant Metastasis.
Zheng Wang, Hui Wang, +5 authors, Kun-Wei Shen.
Front Oncol, 2020 Feb 11; 10. PMID: 32038988    Free PMC article.
Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
Kai-Hua Liu, Lei Zhang, +4 authors, San-Gang Wu.
Breast, 2020 Jan 10; 49. PMID: 31918322    Free PMC article.
LobSig is a multigene predictor of outcome in invasive lobular carcinoma.
Amy E McCart Reed, Samir Lal, +18 authors, Peter T Simpson.
NPJ Breast Cancer, 2019 Jul 03; 5. PMID: 31263747    Free PMC article.
Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
Amy E McCart Reed, Lauren Kalinowski, Peter T Simpson, Sunil R Lakhani.
Breast Cancer Res, 2021 Jan 09; 23(1). PMID: 33413533    Free PMC article.